The DOI matches its Crossref record.
The structural basis of camptothecin interactions with human serum albumin: impact on drug stability
Abstract
The intense intrinsic fluorescence emissions from several clinically relevant camptothecin drugs have been exploited in order to study the structural basis of drug binding to human serum albumin. Both HPLC and time-resolved fluorescence spectroscopic methodologies were employed to characterize the associations of camptothecins with HSA in phosphate-buffered saline (pH 7.4) at 37 degrees C. The alpha-hydroxy delta-lactone ring moiety of camptothecin (C), 10-hydroxycamptothecin (HC), 10,11-(methylenedioxy)camptothecin (MC) and 9-chloro-10,11-(methylenedioxy)camptothecin (CMC) was in each case observed to hydrolyze more rapidly and completely in the presence of HSA than in the protein's absence. Binding isotherms constructed by the method of fluorescence lifetime titration showed that HSA bound preferentially the carboxylate forms of C, HC, MC, and CMC over their lactone forms, thereby providing an explanation for the shift to the right in the lactone-carboxylate equilibrium observed for each compound upon HSA addition. In marked contrast, three analogues (SN-38, CPT-11, and topotecan) all displayed enhanced stabilities in the presence of HSA. While the lifetimes of CPT-11, topotecan, and the carboxylate forms of both drugs were insensitive to the addition of HSA, the lifetimes of both SN-38 and its carboxylate form did titrate upon HSA addition. Analysis of binding isotherms constructed for the albumin interactions of SN-38 and its carboxylate form demonstrated a higher overall association constant for the lactone form [640 (M amino acid (aa) residues)-1] relative to the carboxylate form [150 (M aa)-1]. Our studies indicate that specific modifications at the 7- and 9-positions of the quinoline nucleus, such as those contained in CPT-11, topotecan, and SN-38, enhance drug stability in the presence of HSA. In the case of SN-38, the enhanced stability was shown to be due to preferential associations between the drug's lactone form and the blood protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
PEGylated Nanographene Oxide for Delivery of Water-Insoluble Cancer Drugs
Liu, Z., Robinson, J. T., Sun, X., & Dai, H. (2008) · Journal of the American Chemical Society · doi:10.1021/ja803688x · Cited by 3,589
Protease Inhibitors: Current Status and Future Prospects
Leung, D., Abbenante, G., & Fairlie, D. P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990412m · Cited by 883
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
Pommier, Y. (2009) · Chemical Reviews · doi:10.1021/cr900097c · Cited by 707
Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism
Froelich-Ammon, S. J., & Osheroff, N. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.37.21429 · Cited by 505
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Topoisomerases as anticancer targets
Delgado, J. L., Hsieh, C.-M., Chan, N.-L., & Hiasa, H. (2018) · Biochemical Journal · doi:10.1042/bcj20160583 · Cited by 481
Yang, S. C., Lu, L. F., Cai, Y., Zhu, J. B., Liang, B. W., & Yang, C. Z. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00007-3 · Cited by 476
Nepali, K., Sharma, S., Sharma, M., Bedi, P. M. S., & Dhar, K. L. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.03.018 · Cited by 435
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
Zsila, F. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400027q · Cited by 387
Cheetham, A. G., Chakroun, R. W., Ma, W., & Cui, H. (2017) · Chem. Soc. Rev. · doi:10.1039/c7cs00521k · Cited by 367
Body Distribution of Camptothecin Solid Lipid Nanoparticles After Oral Administration
Yang, S., Zhu, J., Lu, Y., Liang, B., & Yang, C. (1999) · Pharmaceutical Research · doi:10.1023/a:1018888927852 · Cited by 324
Slatter, J. G., Schaaf, L. J., Sams, J. P., Feenstra, K. L., Johnson, M. G., Bombardt, P. A., Cathcart, K. S., Verburg, M. T., Pearson, L. K., Compton, L. D., et al. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15060-x · Cited by 302
Differential Interactions of Camptothecin Lactone and Carboxylate Forms with Human Blood Components
Mi, Z., & Burke, T. G. (1994) · Biochemistry · doi:10.1021/bi00200a013 · Cited by 300
Self-citationInjectable chitosan hydrogels for localised cancer therapy
Ta, H. T., Dass, C. R., & Dunstan, D. E. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.11.018 · Cited by 287
Clinical Pharmacokinetics of Irinotecan
Chabot, G. G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733040-00001 · Cited by 282
Binding of PFOS to Serum Albumin and DNA: Insight into the Molecular Toxicity of Perfluorochemicals
Zhang, X., Chen, L., Fei, X.-C., Ma, Y.-S., & Gao, H.-W. (2009) · BMC Molecular Biology · doi:10.1186/1471-2199-10-16 · Cited by 119
Metadata
- Authors
- Burke, T. G., & Mi, Z.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1994-01
- Volume
- 37
- Issue
- 1
- Pages
- 40-46
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1975616471
- Cited by
- 331
- References
- 0
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.